MedPath
Found 11 clinical trials|View Analysis
Sort by:

A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma

Phase 3
Recruiting
Conditions
Non-small Cell Lung Adenocarcinoma
Squamous Cell Carcinoma of Lung
Interventions
Drug: SI-B001
Drug: Docetaxel
First Posted Date
2023-07-13
Last Posted Date
2024-07-18
Lead Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Target Recruit Count
584
Registration Number
NCT05943795
Locations
🇨🇳

Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

Study of the CHK1 Inhibitor BBI-355, an EcDNA-directed Therapy (ecDTx), in Subjects with Tumors with Oncogene Amplifications

Phase 1
Recruiting
Conditions
Liposarcoma
Non-small Cell Lung Cancer
Breast Cancer
Bladder Cancer
Non-Small Cell Lung Adenocarcinoma
Esophageal Cancer
Gastric Cancer
Non-Small Cell Squamous Lung Cancer
Head and Neck Squamous Cell Carcinoma
Ovarian Cancer
Interventions
First Posted Date
2023-04-25
Last Posted Date
2024-12-20
Lead Sponsor
Boundless Bio
Target Recruit Count
150
Registration Number
NCT05827614
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

UCLA Medical Center, Los Angeles, California, United States

🇺🇸

Sarcoma Oncology, Santa Monica, California, United States

and more 12 locations

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Phase 2
Terminated
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Drug: MORAb-202
First Posted Date
2022-10-13
Last Posted Date
2024-11-13
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
50
Registration Number
NCT05577715
Locations
🇺🇸

Rocky Mountain Cancer Centers - Lone Tree, Lone Tree, Colorado, United States

🇺🇸

Clermont Oncology Center, Clermont, Florida, United States

🇺🇸

Mid Florida Cancer Center - Orange City, Orange City, Florida, United States

and more 26 locations

Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC Adenocarcinoma

Phase 1
Terminated
Conditions
Non-small Cell Lung Cancer Adenocarcinoma
Interventions
First Posted Date
2018-10-04
Last Posted Date
2021-02-21
Lead Sponsor
Arrys Therapeutics
Target Recruit Count
18
Registration Number
NCT03696212
Locations
🇺🇸

Stanford University Medical Center, Stanford, California, United States

🇺🇸

START Midwest, Grand Rapids, Michigan, United States

🇺🇸

Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

and more 3 locations

Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC

Phase 2
Conditions
EGFR Positive Non-Small Cell Lung Cancer,Adenocarcinoma
Interventions
First Posted Date
2018-01-18
Last Posted Date
2018-01-18
Lead Sponsor
Peking University Cancer Hospital & Institute
Target Recruit Count
30
Registration Number
NCT03402464
Locations
🇨🇳

Beijing Cancer Hospital, Beijing, China

A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat

Phase 1
Completed
Conditions
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
Interventions
Biological: PDR001
Drug: QBM076
Drug: HDM201
Drug: LCL161
Drug: Everolimus
Drug: Panobinostat
First Posted Date
2016-09-07
Last Posted Date
2023-01-11
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
298
Registration Number
NCT02890069
Locations
🇺🇸

Huntsman Cancer Institute, Salt Lake City, Utah, United States

🇬🇧

Novartis Investigative Site, Oxford, United Kingdom

🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

and more 7 locations

A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

Phase 3
Terminated
Conditions
Non-Small-Cell Lung Adenocarcinoma
Non-small Cell Lung Cancer Stage IIIB
Non-small Cell Lung Cancer Stage IV
Non-small Cell Lung Cancer Metastatic
Interventions
First Posted Date
2013-02-25
Last Posted Date
2016-07-01
Lead Sponsor
Synta Pharmaceuticals Corp.
Target Recruit Count
696
Registration Number
NCT01798485
Locations
🇺🇸

VA Greater Los Angeles Healthcare System, Los Angeles, California, United States

🇺🇸

Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

🇺🇸

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States

and more 200 locations

Observational Study on the Management of Patients With Non Small Cell Lung Cancer Adenocarcinoma

Completed
Conditions
Non Small Cell Lung Cancer
First Posted Date
2010-07-22
Last Posted Date
2012-09-10
Lead Sponsor
AstraZeneca
Target Recruit Count
2000
Registration Number
NCT01167972
Locations
🇫🇷

Research Site, Yerres, France

A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma

Phase 1
Completed
Conditions
Non-Small Cell Lung Cancer
Adenocarcinoma
First Posted Date
2010-01-20
Last Posted Date
2017-07-02
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
2
Registration Number
NCT01051934
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath